HealthQuill Articles by: HealthQuill
A virus belonging to the bat family, and closely related to the deadly Middle East respiratory syndrome coronavirus (MERS-CoV), may be a small mutation away from spilling over to humans and causing a pandemic.
Climate Health Research

Bat family virus, similar to MERS-CoV, has potential to cause a pandemic

 HQ Team June 9, 2025: A virus belonging to the bat family, and closely related to the deadly Middle East respiratory syndrome coronavirus

Read More
Mental disorders have risen 70% across three decades, starting in 1990, in the Association of Southeast Asian Nations (ASEAN), affecting 80 million people in the region, according to a study.
Drugs Health Research

Mental disorders in ASEAN rise 70% in three decades: IHME, NUS study

HQ Team June 5, 2025: Mental disorders have risen 70% across three decades, starting in 1990, in the Association of Southeast Asian Nations

Read More
Pfizer Inc. will pay Basilea Pharmaceutica Ltd. $ 2.5 million as the Swiss biopharmaceutical company exceeded the sales threshold of its antifungal therapy in the Asia Pacific region, triggering a milestone payment.
Drugs Health Pharma

Sales surge triggers Pfizer’s $2.5 million milestone payment to Basilea

HQ Team June 5, 2025: Pfizer Inc. will pay Basilea Pharmaceutica Ltd. $ 2.5 million as the Swiss biopharmaceutical company exceeded the sales

Read More
Paradromics Inc., a US-based neurotechnology company, has completed its first-in-human surgical placement of its brain-computer interface.
Drugs Health Medical

Paradromics places brain-computer device in human, rivals Neuralink

HQ Team June 5, 2025: Paradromics Inc., a US-based neurotechnology company, has completed its first-in-human surgical placement of its brain-computer interface. The safe

Read More
Eli Lilly and Company and Sweden’s Camurus AB have signed a $870 million pact to develop incretin products for diabetes and other chronic diseases.
Drugs Health Pharma

Lilly, Sweden’s Camurus sign $870 million pact for incretin products

HQ Team June 4, 2025: Eli Lilly and Company and Sweden’s Camurus AB have signed a $870 million pact to develop incretin products

Read More
British-Swedish AstraZeneca Plc.’s investigational pill to treat an advanced breast cancer has reduced the chance of worsening the disease or the patient dying by 56% compared to the usual treatment.
Drugs Health Pharma

AstraZeneca’s pill to treat breast cancer cuts disease worsening by 56%

HQ Team June 4, 2025: British-Swedish AstraZeneca Plc.’s investigational pill to treat an advanced breast cancer has reduced the chance of worsening the

Read More
A third of patients with a type of blood cancer, especially those whose disease had returned or not responded to other treatments, have shown “promising” results in an early Johnson & Johnson trial.
Drugs Health Pharma

A third of blood cancer cases in J&J trials live without detectable cancer 

HQ Team June 4, 2025: A third of patients with a type of blood cancer, especially those whose disease had returned or not

Read More
Billionaire Elon Musk’s Neuralink has raised $650 million in Series E funding from key investors and its clinical trials for brain implant devices have started in three countries.
Drugs Health Pharma

Musk’s Neurolink raises $650 million, brain implant trials start in 3 countries

HQ Team June 3, 2025: Billionaire Elon Musk’s Neuralink has raised $650 million in Series E funding from key investors and its clinical

Read More
Definitive evidence has emerged from a global colon cancer trial that people who follow a structured exercise programme after surgery and chemotherapy have better odds of survival and lower risk of cancer coming back.
Drugs Health Research

Exercise helps colon cancer patients live longer, lowers recurrence rate

HQ Team June 3, 2025: Definitive evidence has emerged from a global colon cancer trial that people who follow a structured exercise programme

Read More
AstraZeneca and Daiichi Sankyo’s breast cancer drug, Enhertu, has cut the risk of disease progression or death by 44% compared to a taxane, trastuzumab and pertuzumab combination. 
Drugs Health Pharma

AstraZeneca, Daiichi’s Enhertu cuts breast cancer progression by 44%

HQ Team June 3, 2025: AstraZeneca and Daiichi Sankyo’s breast cancer drug, Enhertu, has cut the risk of disease progression or death by

Read More